Cancer diagnosis using nucleic acid hybridization
US5688641A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 13, 1994 |
| Grant date | Nov 18, 1997 |
| Priority date | — |
| Expiry date | Oct 13, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of determining whether a test cell from a given human tissue type is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of the test cell with a nucleic acid probe which contains a nucleotide sequence at least 15 nucleotides in length which is complementary to a portion of the coding sequence of a candidate tumor suppressor gene, which gene is one that is expressed at a given control level in normal cells of that tissue type; and determining the approximate amount of hybridization of the probe to the mRNA of the test cell, an amount of hybridization one-third or less that seen with the mRNA of a normal cell of that tissue type being an indication that the test cell is cancerous or precancerous. Alternatively, an antibody specific for the candidate tumor suppressor gene product can be substituted for the nucleic acid probe as a means for determining the level of expression of the gene in the test cell. The invention also includes methods of treating a cancerous cell by increasing the level of expression of a candidate tumor suppression gene in the cell; novel candidate tumor suppressor genes; and their use in diagnosis, prognosis, and therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.